Pharmacokinetic studies of a transplantable murine renal adenocarcinoma.
An animal model to investigate new therapeutic approaches for the treatment of renal adenocarcinoma has been further studied. This model is based on a transplantable murine renal adenocarcinoma whose growth follows Gompertzian kinetics, relates to tumor RNA and DNA content, and also correlates with the rate of tumor DNA synthesis. This model in the current study was also evaluated for the ability of various therapeutic agents to inhibit tumor DNA synthesis. Such tests may be valuable for the preclinical screening of potentially useful drugs and may provide insight into fundamental aspects of tumor control. In this study, CCNU, BCNU, and adriamycin were potent inhibitors of tumor DNA synthesis whereas cytosine arabinoside, bleomycin, and cyclophosphamide were not. These observations were confirmed by autoradiography and correlated with other experimental end points of tumor therapy such as tumor weight and animal survival. This preclinical screening model is an effective and helpful means whereby new drugs and drug combinations can be tested for potential use in human renal cell carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism*; D000818:Animals; D001761:Bleomycin / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D008130:Lomustine / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism*
D003561:Cytarabine; D001761:Bleomycin; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002330:Carmustine